tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Lipella Pharmaceuticals completes enrollment in LP-310 trial

Lipella Pharmaceuticals (LIPO) announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus. The Phase 2a trial has now fully enrolled participants across all three dose cohorts at seven U.S. study sites. Topline results from the final cohort remain on track for the second quarter of 2025 and will represent the most comprehensive clinical dataset to date for LP-310.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1